Skip to main content
Premium Trial:

Request an Annual Quote

Genoptix Licenses Rights to HistoRx Aqua Tech

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Lab services provider Genoptix said today that it has signed a license and collaboration agreement with HistoRx covering cancer biomarker analysis technologies in the US.

The license gives Carlsbad, Calif.-based Genoptix the exclusive commercial laboratory rights to develop and perform in the US three solid tumor assays using HistoRx's Aqua technology. In addition, it has gained non-exclusive rights to use Aqua to measure two other biomarkers that have been associated with many cancers.

The Aqua technology is used in fluorescent immunohistochemstry analysis, and enables users to assess specific biomarkers for patients with solid tumors by measuring the protein in a cell's cytoplasm or nucleus.

Under the agreement, Genoptix and HistoRx may collaborate to develop additional assays that Genoptix would then have the rights to commercialize. Financial terms of the agreement were not released.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.